πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

7,888 results for β€œ1” Clear

  1. METHOTREXATE, Dazukibart, AZATHIOPRINE, HYDROCORTISONE, DEXAMETHASONE, METHYLPREDNISOLONE, CHLOROQUINE PHOSPHATE, MYCOPHENOLATE MOFETIL, BETAMETHASONE, METHYLPREDNISOLONE, PREDNISOLONE, TRIAMCINOLONE ACETONIDE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, DEFLAZACORT, BETAMETHASONE, PREDNISONE, BUDESONIDE, METHOTREXATE

    Pfizer Australia Pty Ltd

    Idiopathic Inflammatory Myopathy (including dermatomyositis or polymyositis)

    phase 3 small molecule active

    1 trial

  2. METHOTREXATE, IFOSFAMIDE, VINCRISTINE, CYCLOPHOSPHAMIDE, RITUXIMAB, ETOPOSIDE, CYTARABINE, PREDNISOLONE, DOXORUBICIN

    Wuhan Createrna Science and Technology Co., Ltd

    Burkitt lymphoma

    phase 3 small molecule active

    1 trial

  3. METHOTREXATE, INFLIXIMAB, AZATHIOPRINE

    Pari Pharma GmbH

    Immune system disorders

    phase 3 small molecule active

    1 trial

  4. METHOTREXATE, METHOTREXATE, DESOXIMETASONE, TACROLIMUS, placebo, Acidum folicum Léčiva 10 mg obalené tablety, FOLIC ACID

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    moderate to severe atopic dermatitis

    phase 3 small molecule active

    1 trial

  5. METHYLPREDNISOLONE , CellCept 500 mg film-coated tablets, PREDNISONE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , ANAKINRA , RoActemra 20 mg/mL concentrate for solution for infusion, DEXAMETHASONE , Acasunlimab

    Genmab A/S

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. METHYLPREDNISOLONE , PREDNISONE , Gazyvaro 1,000 mg concentrate for solution for infusion., Obinutuzumab placebo, Myfenax 500 mg film-coated tablets, DIPHENHYDRAMINE , PARACETAMOL

    Hoffmann-La Roche

    Lupus Nephritis (LN)

    phase 3 small molecule active

    1 trial

  7. METHYLPREDNISOLONE, Axatilimab (INCA034176), Placebo, PREDNISONE

    Incyte

    chronic graft-versus-host disease

    phase 3 small molecule active

    1 trial

  8. METHYLPREDNISOLONE, Placebo of CRESEMBA, CRESEMBA 200 mg powder for concentrate for solution for infusion, Placebo of methylprednisolone

    Pari Pharma GmbH

    patients with acute respiratory failure from undetermined etiology

    phase 3 small molecule active

    1 trial

  9. METOCLOPRAMIDE , -, SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion, OCTREOTIDE

    Novartis Pharmaceuticals

    Gastroenteropancreatic neuroendocrine tumor (GEP-NET)

    phase 3 small molecule active

    1 trial

  10. METYRAPONE ESTEVE 250 mg, capsule molle, Placebo of metyrapon 250 mg

    Pari Pharma GmbH

    Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cushing Syndrome (Mild autonomous Cortisol secretion)

    phase 3 small molecule active

    1 trial

  11. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    NASH - Nonalcoholic Steatohepatitis

    phase 3 small molecule active

    1 trial

  12. MGL-3196 80 mg oral, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 60 mg film-coated tablet, MGL-3196 60 mg oral, MGL-3196 100 mg oral, Matching placebo MGL-3196 100 mg film-coated tablet

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis (NASH) Cirrhosis

    phase 3 small molecule active

    1 trial

  13. MIDAZOLAM , CEDACONDA 100 % V/V, liquide pour inhalation par vapeur, PROPOFOL

    Pari Pharma GmbH

    Adult patients with severe cardiogenic shock on venoarterial ECMO support for less than 24 hours.

    phase 3 small molecule active

    1 trial

  14. MIDAZOLAM, DEXMEDETOMIDINE EVER PHARMA 100 microgrammes/mL, solution Γ  diluer pour perfusion

    Pari Pharma GmbH

    Very preterm neonate (gestational age at birth < 32 WG) with corrected gestational age <45 WG) with indication for sedation in the context of invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  15. MIDOSTAURIN, ARACYTIN 500 mg/10 ml Polvere e Solvente per Soluzione Iniettabile, DAUNORUBICIN HYDROCHLORIDE

    Fondazione Telethon ETS

    Acute Myeloid Leukemia (LMA) with FLT3 mutation

    phase 3 small molecule active

    1 trial

  16. MINJUVI 200 mg powder for concentrate for solution for infusion

    Incyte

    Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimmune hemolytic anemia

    phase 3 small molecule active

    1 trial

  17. MITAPIVAT, MITAPIVAT, "Placebo to Match Mitapivat Tablets, 5 mg and 20 mg, are supplied as film-coated, blue, round tablets for oral administration Placebo to Match Mitapivat Tablets, 50 mg or 100 mg, are supplied as film-coated, blue, oblong tablets for oral administration. Placebo to Match Mitapivat Granules, 1 mg, are supplied as film-coated, white, round granules for oral administration", MITAPIVAT

    Lacuna Pharma Pty Ltd

    Anemia in subjects with sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  18. MITAPIVAT, Placebo for Mitapivat

    Lacuna Pharma Pty Ltd

    Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial

  19. MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  20. MK-0616, Placebo to MK-0616

    Merck Sharp and Dohme

    ​Heterozygous Familial Hypercholesterolemia​ in pediatric patients

    phase 3 small molecule active

    1 trial

  21. MK-0616, Placebo to MK-0616 - Tablet

    Merck Sharp and Dohme

    ASCVD - Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  22. MK-1022, CAPECITABINE , PACLITAXEL , TRASTUZUMAB DERUXTECAN , PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN , DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  23. MK-1084, MK-3475A, CARBOPLATIN , PEMETREXED , MK-1084, CISPLATIN , Placebo for MK-1084

    Merck Sharp and Dohme

    Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC

    phase 3 small molecule active

    1 trial

  24. MK-2870, GEMCITABINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , -, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL

    Merck Sharp and Dohme

    Locally recurrent unresectable or metastatic TNBC with tumors expressing PD-L1 at the cut-off of CPS <10

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources